Table 2.
Univariate analysis of potential prognostic factors for survival.
| Variable | Hazard Ratio (95% CI) | p-value | |
|---|---|---|---|
| Clinicopathological factors | |||
| ECOG-PS | 0.136 | ||
| 0 vs 1 | 0.488 (0.067 - 3.561) | 0.479 | |
| 0 vs 2 | 0.623 (0.084 - 4.602) | 0.643 | |
| 0 vs 3 | 0.927 (0.116 - 7.384) | 0.943 | |
| 0 vs 4 | 1.551 (0.161 - 14.956) | 0.704 | |
| BMI (kg/m2) | 0.135 | ||
| <18.5 vs 18.5-22.9 | 0.577 (0.327 - 1.019) | 0.058 | |
| <18.5 vs ≥23 | 0.581 (0.327 - 1.033) | 0.064 | |
| Tumor Site | Colon / Rectum | 0.808 (0.529 - 1.236) | 0.326 |
| Liver Metastasis | No / Yes | 1.567 (1.060 - 2.317) | 0.024 |
| Prior Surgery | No / Yes | 0.864 (0.542 - 1.378) | 0.539 |
| Prior Chemotherapy | 0.275 | ||
| None vs 1st line | 0.501 (0.238 - 1.051) | 0.068 | |
| None vs 2nd line | 0.617 (0.330 - 1.153) | 0.130 | |
| None vs ≥3rd line | 0.729 (0.410 - 1.297) | 0.282 | |
| Prior Radiotherapy | No / Yes | 0.767 (0.504 - 1.166) | 0.214 |
| Laboratory factors | |||
| Hb (g/dL) | <12 / ≥12 | 0.654 (0.450 - 0.950) | 0.026 |
| Albumin (g/dL) | <3.5 / ≥3.5 | 0.402 (0.219 - 0.736) | 0.003 |
| CRP (mg/L) | <10.0 / ≥10.0 | 2.869 (1.924 - 4.280) | 0.000 |
| PLT (× 103/μL) | <400 / ≥400 | 1.760 (0.909 - 3.406) | 0.093 |
| Ferritin (ng/mL) | <150 / ≥150 | 1.878 (1.268 - 2.781) | 0.002 |
| CEA (ng/mL) | ≤5 / >5 | 1.668 (1.015 - 2.743) | 0.044 |
| CA19-9 (U/mL) | ≤27 / >27 | 1.305 (0.858 - 1.984) | 0.213 |
| WBC (× 103/μL) | <10.0 / ≥10.0 | 1.627 (0.872 - 3.035) | 0.126 |
| ANC (cells/μL) | ≤4336.0 / >4336.0 | 1.444 (0.995 - 2.096) | 0.053 |
| ALC (cells/μL) | ≤1291.1 / >1291.1 | 0.827 (0.570 - 1.198) | 0.315 |
| AMC (cells/μL) | ≤413.3 / >413.3 | 1.517 (1.033 - 2.229) | 0.034 |
ECOG-PS = Eastern Cooperative Oncology Group performance status; BMI = body mass index; Hb = hemoglobin; CRP = C-reactive protein; PLT = platelets; CEA = carcinoembryonic antigen; CA19-9 = carbohydrate antigen 19-9; WBC = white blood cell; ANC = absolute neutrophil count; ALC = absolute lymphocyte count; AMC = absolute monocyte count.